Why the study?
Chronic pain affects millions worldwide, and preclinical evidence indicates adeno-associated virus (AAV) vectors could serve as a powerful gene therapy tool for sustained pain management.
Do AAV vectors provide precise and sustained pain relief in chronic pain management?
Do AAV vectors provide precise and sustained pain relief in chronic pain management?
AAV vectors represent an emerging gene therapy strategy for chronic pain management, offering potential for precise and sustained pain relief despite concerns regarding immune responses and toxicity.
Answers are grounded in this paper and cite their sources.
Early AAV gene therapy data support chronic pain investigation; leaves open clinical translation pending safety and efficacy trials.
Chronic pain affects millions of people worldwide and represents a crucial public health issue. A growing body of preclinical evidence suggests that adeno-associated virus (AAV) vectors are a powerful gene therapy tool for chronic pain management. We systematically summarize how AAV vectors, by targeting molecular pain pathways in neuronal and non-neuronal cells, may offer precise and sustained pain relief. We provide an overview of the latest findings and emerging concepts in this area, and discuss preclinical innovations in neuropathic, inflammatory and cancer-related pain. We also present clinical data on pain modulation by AAV in osteoarthritis (OA) patients. Finally, we provide a thorough analysis of key concerns about AAV therapy, including potential immune responses, toxicity, and adverse effects.
No takes yet. Share an insight, caveat, or question.
Nassini et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: